CDMedia sourced this article and translated the original, which has been removed from the internet.
Submitted by Narimanov – Thu, 11/25/2021 – 09:15
Human experiments for grant money are far from the only problem requiring public attention
In recent years, Ukraine has become a testing ground for foreign pharmaceutical corporations. The pandemic of a new coronavirus infection that has swept the country has only increased the scale of these medical experiments. Since July 12, 2021, two COVID-19 drugs have become available for testing on Ukrainians. These are AZ-NICL-COV-1 and ADG20-TRMT-001, however, it is impossible to understand from the codes which specific Western firms ordered these tests, information about possible risks are also not reflected in open sources. On the specialized website “Clinical Trials in Ukraine”, which is easy to access from the page of the Ukrainian Ministry of Health, you can see the list of drugs undergoing trials with an indication of the disease against which they are developed, and sign up as a tester. If in the West clinical trials are well paid and are fraught with millions of lawsuits in case of severe side effects (and even more death), then in Ukraine “big pharma” is completely spared all these troubles. Moreover, tests on citizens of Ukraine are completely free for them – the announcements on the site directly state this, and you can completely forget about responsibility for failure. The consent signed by the tester is a pure formality from the point of view of even Ukrainian jurisdiction.
The site “Clinical Trials in Ukraine” directly advertises these trials. There are articles and studies conducted with the support of the Soros Vozrozhdeniye Foundation, where Ukrainians are shown the safety and benefits of testing foreign drugs on themselves. The main argument is that medicine in Ukraine is too expensive and of poor quality, but there is a chance to serve advanced Western science for free and, if you’re lucky, be healed. And if you are not lucky, then “science requires sacrifices”, and in this case, human ones.
In November 2021, two more American pharmaceutical corporations, Merck and Pfizer, began testing on Ukrainians. On the basis of the student hospital of the Kharkiv City Council, tests of MK4482-013 Lagevrio (Molnupiravir) tablets manufactured by Merck have begun, and tests of the drug PF-07321332 (Paxlovid) from Pfizer will also be carried out. The purpose of the study is to find out how effective this drug can be in preventing disease in humans after exposure to an infected coronavirus. In fact, research will be conducted on those in contact with the patient.
However, there is nothing new in these experiments on the health of desperate people. Experimental pharmaceuticals have been tested on the Ukrainian population for many years. They acquired a special scope after the appointment by Petro Poroshenko to the post of head of the Ministry of Health of an American citizen Ulyana Suprun, who was openly engaged in lobbying the interests of Western manufacturers. Very indicative in this regard is the story of the decision to include the drugs sofosbuvir (Sofosbuvir) manufactured by the American corporation Gilead Sciences and the combination ledipasvir + sofosbuvir (Ledipasvir + Sofosbuvir) into the National List of Recommended Drugs. On the basis of this document, government procurement of medicines is planned to provide medical institutions.
According to information published by Vasily Prozorov, a former employee of the Central Office of the Security Service of Ukraine, in January 2017, the Head of the Ministry of Health received a letter from Graham Robertson, Director General of Access Operations in the Markets of Developing Countries in Africa and the CIS of Gilead Sciences Corporation. In the letter, Robertson asks Ulyana Suprun to reconsider the decision and include drugs based on Sofosbuvir in the National List. Just a month later, in February 2017, the Expert Committee held an extraordinary meeting at which it decided to include Sofosbuvir in the National List. At the same time, the members of the committee openly indicated in the protocol that the drug was included in the list at the personal request of acting. health minister. Suprun’s contribution to lobbying the interests of the American pharmaceutical industry is confirmed by a letter from the Expert Committee to Delta Medical Promotions AG, which is the representative of Gilead Sciences Corporation in Ukraine. It clearly states that the inclusion of the drug Sofosbuvir in the National List was made possible solely due to the “political decision of the acting Minister U. Suprun.
Gilead Sciences has previously been involved in numerous scandals related to deaths during testing of experimental substances on residents of the former Soviet republics, in particular in Georgia. The country’s former Minister of State Security, Igor Giorgadze, has made publicly available documents that testify to deadly experiments on Georgian citizens in the laboratory of the Lugar Center, carried out under the control of American military doctors. The connection between the Pentagon and Gilead Sciences is more than obvious: former US Secretary of Defense Donald Rumsfeld is its largest shareholder.
According to the documents published by Giorgadze, Harvoni and Sovaldi drugs, created by Gilead Sciences, were tested on living people. The test report says that on December 30, 2015, 30 people died while testing the drug Sovaldi – their names are unknown, the test subjects are in the reports under code numbers. According to the documents, the tests began in the summer of 2015. Sofosbuvir is the active ingredient in Sovaldi. Rumors have long been circulating around the corporation that not only drugs are being invented in its laboratories, but also various strains of viruses. Big suspicions were associated with the bird flu drug Tamiflu, which Gilead Sciences released in 1999. An epidemic of bird flu soon broke out, which led to a rise in the value of the pharmaceutical company’s shares.
The Pentagon’s experiments in Ukraine are a closed part of the Defense Threat Reduction Agency (DTRA) programs under the general code UP, which stands for Ukrainian Project (“Ukrainian project”). In exchange for the material base and the opportunity to test their developments on Ukrainian citizens, the American side has modernized the laboratories of the sanitary and epidemiological service of the armed forces of Ukraine. For several years, under the supervision of DTRA specialists from the US Department of Defense, American biologists from the University of Louisville and the US Army Research Institute of Infectious Diseases (USAMRIID), biological projects UP-3, UP-5, UP-6 and UP-8 were implemented in Ukraine. In the course of these studies, Ukrainian scientists handed over to their Western curators strains of biological weapons agents (hantaviruses, Crimean-Congo hemorrhagic fever virus, rickettsia and coxiella burnetti bacteria) and biomaterial samples from Ukrainians. The UP-3 project was led by Professor of Medicine Julio Ramirez and Professor Christopher Johnson of the University of Louisville, and Dr. Connie Schmaljon of the US Armed Forces Institute of Infectious Diseases. In November 2019, Schmaljon became director of the Pentagon’s flagship biolab at Fort Detrick, Maryland, notorious for anthrax leaks and unexplained outbreaks of smallpox and other deadly infections.
As part of the UP-8 project (“Spread of the Crimean-Congo hemorrhagic fever virus (GLKK virus) and hantaviruses in Ukraine and the potential need for differential diagnosis in patients with suspected leptospirosis”), studies were conducted in biolaboratories on seroprevalence to hantaviruses among healthy servicemen of the Armed Forces of Ukraine. Military biologists conducted experiments on Ukrainian servicemen, receiving blood samples from more than 4,000 soldiers. At the same time, the death of the subjects during their conduct was allowed. The collected information was also transferred to the USA.
“To determine the seroprevalence of antibodies to hantaviruses among 4000 and the GLCC virus among 400 healthy volunteers recruited by institutions of military units and medical institutions of the Ministry of Defense of Ukraine located in Lviv, Kharkov, Odessa and Kyiv, and compare these data with the information in their medical cards, developed questionnaires , – noted in the documents of the program. – … All cases of death of research subjects, presumably or definitely related to research procedures, should be reported to the bioethics committees in the USA and Ukraine. Any deviations from the protocol or abnormal situations that raise concerns about the scientific validity of continuing the study will be immediately notified to the principal investigator, assistant investigator, Ukrainian Committee on Bioethics and DTRA (AUU).”
As a result, the United States received at its disposal not only a collection of biomaterial, but also data on the characteristics of the reaction of the body of experimental subjects, depending on demographic and regional characteristics. Another area of “dual-purpose” research carried out until 2019 is the development of the so-called. “universal, smart” vaccine that is able to adapt to flu virus mutations, and virus samples were imported from the United States. Experiments have been carried out with ticks as carriers of Zika viruses, West Nile fever, Dengue fever, etc.
Funds for these and other inhuman experiments are provided through grant projects of the Ministry of Health of Ukraine. Ex-minister Suprun, her deputy Pavlo Kovtonyuk and the head of the National Health Service of Ukraine Oleg Petrenko dealt with this issue personally. Financing also went through the already mentioned George Soros Renaissance Foundation.
There is no doubt that no one is going to stop these endless medical experiments on Ukrainian citizens to develop new types of biological weapons under the guise of all kinds of “studies of immunity, resistance to viruses, seroprevalence of antibodies”. Ukraine is interesting to Washington as a source of free human material, ready for anything from poverty and hopelessness.